| 臺大學術典藏 |
2020-12-18T08:37:37Z |
Predictors of failure of conservative treatment among patients with emphysematous pyelonephritis
|
Pu Y.-S.; Lu Y.-C.; Chiang B.-J.; Pong Y.-H.; Huang K.-H.; PO-REN HSUEH; Huang C.-Y. |
| 臺大學術典藏 |
2020-11-27T08:14:49Z |
Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: A potential use in intravesical chemotherapy
|
Pu Y.-S.;Hsieh T.-S.;Cheng A.-L.;Tseng N.-F.;Su I.-J.;Chang-Yao Hsieh;Lai M.-K.;Tsai T.-C.; Pu Y.-S.; Hsieh T.-S.; Cheng A.-L.; Tseng N.-F.; Su I.-J.; CHANG-YAO HSIEH; Lai M.-K.; Tsai T.-C. |
| 臺大學術典藏 |
2020-11-27T08:14:49Z |
Expression of mdr-1 gene in transitional cell carcinoma and its correlation with chemotherapy response
|
Pu Y.-S.;Tsai T.-C.;Cheng A.-L.;Tsai C.-Y.;Tseng N.-F.;Su I.H.-J.;Chang-Yao Hsieh;Lai M.-K.; Pu Y.-S.; Tsai T.-C.; Cheng A.-L.; Tsai C.-Y.; Tseng N.-F.; Su I.H.-J.; CHANG-YAO HSIEH; Lai M.-K. |
| 臺大學術典藏 |
2020-11-27T08:14:46Z |
Megestrol acetate antagonizes cisplatin cytotoxicity
|
Pu Y.-S.;Cheng A.-L.;Chen J.;Guan J.-Y.;Lu S.-H.;Lai M.-K.;Chang-Yao Hsieh; Pu Y.-S.; Cheng A.-L.; Chen J.; Guan J.-Y.; Lu S.-H.; Lai M.-K.; CHANG-YAO HSIEH |
| 臺大學術典藏 |
2020-11-27T08:14:42Z |
Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines
|
Hour T.-C.;Chen J.;Huang C.-Y.;Guan J.-Y.;Lu S.-H.;Chang-Yao Hsieh;Pu Y.-S.; Hour T.-C.; Chen J.; Huang C.-Y.; Guan J.-Y.; Lu S.-H.; CHANG-YAO HSIEH; Pu Y.-S. |
| 臺大學術典藏 |
2020-11-27T08:14:40Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L.;Hsu C.-H.;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Chang-Yao Hsieh; Chen A.-L.; Hsu C.-H.; Lin J.-K.; Hsu M.-M.; Ho Y.-F.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; CHANG-YAO HSIEH |
| 臺大學術典藏 |
2020-11-27T03:25:07Z |
Quantitative analysis of messenger ribonucleic acid encoding natriuretic peptide receptors in aldosterone-producing adenoma
|
Chen Y.-M.;Wu K.-D.;Kuan-Yu Hung;Pu Y.-S.;Hsieh B.-S.; Chen Y.-M.; Wu K.-D.; KUAN-YU HUNG; Pu Y.-S.; Hsieh B.-S. |
| 臺大學術典藏 |
2020-11-19T03:20:28Z |
RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts
|
Tsuei D.-J.;Hsu H.-C.;Po-Huang Lee;Jeng Y.-M.;Pu Y.-S.;Chen C.-N.;Lee Y.-C.;Chou W.-C.;Chang C.-J.;Ni Y.-H.;Chang M.-H.; Tsuei D.-J.; Hsu H.-C.; PO-HUANG LEE; Pu Y.-S.; Chen C.-N.; Lee Y.-C.; Chou W.-C.; Chang C.-J.; Ni Y.-H.; Chang M.-H.; Jeng Y.-M. |
| 臺大學術典藏 |
2020-11-02T02:05:31Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Hsieh C.-Y.; She T.-S.; Ko J.-Y.; Lin J.-T.; Lin B.-R.; MING-SHIANG WU; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Ho Y.-F.; Hsu M.-M.; Lin J.-K.; Hsu C.-H.; Chen A.-L. |
| 臺大學術典藏 |
2020-09-28T07:04:45Z |
Clinical outcomes in patients undergoing laparoscopic adrenalectomy for unilateral aldosterone producing adenoma: Partial versus total adrenalectomy
|
Chen S.-F.; Chueh S.-C.; Wang S.-M.; Pu Y.-S.; Wu K.-D.; Huang K.-H. |
| 臺大學術典藏 |
2020-08-13T05:24:19Z |
Case report
|
Lin C.-C.; JANN-YUAN WANG; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chih-Hsin Yang;Cheng A.-L;Keng H.-Y;Hsu C.-H;Pu Y.-S;Lin C.-C; Lin C.-C; Pu Y.-S; Hsu C.-H; Keng H.-Y; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Pu Y.-S.;Cheng A.-L;Tsai T.-C;Chen J;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Chen J; Tsai T.-C; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:35Z |
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells
|
Hour T.-C.;Lin S.-R;Guan J.-Y;Chia-Chi Lin;Huang C.-Y;Liu G.-Y;Wang C.-W;Hsieh M.-W;Pu Y.-S; Pu Y.-S; Hsieh M.-W; Wang C.-W; Liu G.-Y; Huang C.-Y; Chia-Chi Lin; Guan J.-Y; Lin S.-R; Hour T.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:35Z |
Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer
|
Hour T.-C; Pu Y.-S; Chia-Chi Lin; Huang S.-W; Chen J; Chiu A.W; Chen C.-J; Huang C.-Y. |
| 臺大學術典藏 |
2020-05-25T07:35:35Z |
Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide
|
Pu Y.-S.;Lee J.-M;Guan J.-Y;Chen J;Chia-Chi Lin;Huang C.-Y;Hour T.-C; Hour T.-C; Huang C.-Y; Chia-Chi Lin; Chen J; Guan J.-Y; Lee J.-M; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:35Z |
Changing trends of prostate cancer in Asia
|
Chen J.;Huang K.-H;Huang C.-Y;Chia-Chi Lin;Chiang H.-S;Pu Y.-S; Pu Y.-S; Chiang H.-S; Chia-Chi Lin; Huang C.-Y; Huang K.-H; Chen J. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Pu Y.-S.;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Pu Y.-S.;Vogelzang N.J;Chen J;Cheng A.-L;Huang C.-Y;Hsu C.-H;Chia-Chi Lin; Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Cheng A.-L; Chen J; Vogelzang N.J; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Keng H.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Tsai Y.-C; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:33Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Chia-Chi Lin; Hsu C.-H; Huang C.-Y; Cheng A.-L; Vogelzang N.J; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Systemic therapy for metastatic urothelial carcinoma
|
Chia-Chi Lin; Hsu C.-H; Pu Y.-S; Vogelzang N.J. |
| 臺大學術典藏 |
2020-05-25T07:35:32Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Chia-Chi Lin; Hsu C.-H; Hour T.-C; Cheng A.-L; Huang C.-Y; Huang K.-H; Chen J; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:31Z |
Down-regulated expression of RhoA in human conventional renal cell carcinoma
|
Hour T.-C.;Wu W.-J;Chia-Chi Lin;Shun C.-T;Kang W.-Y;Huang C.-Y;Kuo Y.-Z;Liu G.-Y;Wang C.-W;Pu Y.-S; Pu Y.-S; Wang C.-W; Liu G.-Y; Kuo Y.-Z; Huang C.-Y; Kang W.-Y; Shun C.-T; Chia-Chi Lin; Wu W.-J; Hour T.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:30Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chia-Chi Lin; Pu Y.-S; Hsu C.-H; Keng H.-Y; Cheng A.-L; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:29Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Huang C.-Y; Cheng J.C; Chia-Chi Lin; Hsu C.-H; Tsai Y.-C; Hsu F.-M; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:24Z |
Reply to S. Vale
|
Chia-Chi Lin; Wang J.-Y; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y; Cheng J.C.-H; Huang C.-Y; Tsai Y.-C; Chia-Chi Lin; Hsu C.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T02:45:40Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C; Hsu C.-H; Cheng J.C; Huang C.-Y; Tsai Y.-C; Feng-Ming Hsu; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T02:45:33Z |
Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma
|
Feng-Ming Hsu; Hou W.-H; Huang C.-Y; Wang C.-C; Tsai C.-L; Tsai Y.-C; Yu H.-J; Pu Y.-S; Cheng J.C.-H. |
| 臺大學術典藏 |
2020-05-19T02:02:44Z |
Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: Systematic review and network meta-analysis
|
Yu-Kang Tu;Pu Y.-S.;Chien K.-L.;Yeh Y.-C.;Shih M.-C.;Tseng C.-S.;Tsai C.-Y.;Huang S.-W.; Huang S.-W.; Tsai C.-Y.; Tseng C.-S.; Shih M.-C.; Yeh Y.-C.; Chien K.-L.; Pu Y.-S.; YU-KANG TU |
| 臺大學術典藏 |
2020-04-28T07:25:40Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.;Chih-Hung Hsu;Chen J.;Tsai T.-C.;Cheng A.-L.;Pu Y.-S.; Lin C.-C.; CHIH-HUNG HSU; Chen J.; Tsai T.-C.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-28T07:25:40Z |
Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
|
Chih-Hung Hsu;Chen J.;Wu C.-Y.;Cheng A.-L.;Pu Y.-S.; CHIH-HUNG HSU; Chen J.; Wu C.-Y.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-28T07:25:39Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Wu M.-S.; Yu H.-S.; Jee S.-H.; Chen G.-S.; Chen T.-M.; Chen C.-A.; Lai M.-K.; Pu Y.-S.; Pan M.-H.; Wang Y.-J.; Tsai C.-C.; Hsieh C.-Y.; Lin B.-R.; Lin J.-T.; Ko J.-Y.; She T.-S.; Ho Y.-F.; CHIH-HUNG HSU; Lin J.-K.; Hsu M.-M.; Chen A.-L.; Chen A.-L.;Chih-Hung Hsu;Lin J.-K.;Hsu M.-M.;Ho Y.-F.;She T.-S.;Ko J.-Y.;Lin J.-T.;Lin B.-R.;Wu M.-S.;Yu H.-S.;Jee S.-H.;Chen G.-S.;Chen T.-M.;Chen C.-A.;Lai M.-K.;Pu Y.-S.;Pan M.-H.;Wang Y.-J.;Tsai C.-C.;Hsieh C.-Y. |
| 臺大學術典藏 |
2020-04-28T07:25:34Z |
Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study
|
Lin C.-C.;Chih-Hung Hsu;Pu Y.-S.; Lin C.-C.; CHIH-HUNG HSU; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-28T07:25:34Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.;Chih-Hung Hsu;Huang C.-Y.;Cheng A.-L.;Chen J.;Vogelzang N.J.;Pu Y.-S.; Lin C.-C.; CHIH-HUNG HSU; Huang C.-Y.; Cheng A.-L.; Chen J.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-28T07:25:32Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Pu Y.-S.;Cheng A.-L.;Huang K.-H.;Tsai Y.-C.;Huang C.-Y.;CHIH-HUNG HSU;Lin C.-C.; Lin C.-C.; CHIH-HUNG HSU; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-28T07:25:28Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; Pu Y.-S.; CHIH-HUNG HSU; Lin C.-C.;Chih-Hung Hsu;Cheng J.C.;Huang C.-Y.;Tsai Y.-C.;Hsu F.-M.;Huang K.-H.;Cheng A.-L.;Pu Y.-S.; Lin C.-C. |
| 臺大學術典藏 |
2020-04-28T07:25:14Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Tsai Y.-C.; Chiang Y.;Cheng J.C.-H.;Huang C.-Y.;Tsai Y.-C.;Lin C.-C.;Chih-Hung Hsu;Cheng A.-L.;Pu Y.-S.; Chiang Y.; Cheng J.C.-H.; Huang C.-Y.; Lin C.-C.; CHIH-HUNG HSU; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2020-04-27T08:45:14Z |
Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells
|
Tsai Y.-C.;Ho P.-Y.;Tzen K.-Y.;Tuan T.-F.;Liu W.-L.;Cheng A.-L.;Pu Y.-S.;Chia-Hsien Cheng; Tsai Y.-C.; Ho P.-Y.; Tzen K.-Y.; Tuan T.-F.; Liu W.-L.; Cheng A.-L.; Pu Y.-S.; CHIA-HSIEN CHENG |
| 臺大學術典藏 |
2020-04-27T08:45:09Z |
Comparative analysis between radical cystectomy and trimodality therapy for clinical Stage II Bladder Cancer: Experience from a tertiary referral center
|
Hong J.-H.;Lin Y.-H.;Lu Y.-C.;Chiang Y.;Tai H.-C.;Huang K.-H.;Chia-Hsien Cheng;Pu Y.-S.; Huang K.-H.; CHIA-HSIEN CHENG; Pu Y.-S.; Tai H.-C.; Hong J.-H.; Lin Y.-H.; Lu Y.-C.; Chiang Y. |
| 臺大學術典藏 |
2020-04-27T08:45:09Z |
A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement
|
Chiang Y.;Chia-Hsien Cheng;Huang C.-Y.;Tsai Y.-C.;Lin C.-C.;Hsu C.-H.;Cheng A.-L.;Pu Y.-S.; Chiang Y.; CHIA-HSIEN CHENG; Huang C.-Y.; Tsai Y.-C.; Lin C.-C.; Hsu C.-H.; Cheng A.-L.; Pu Y.-S. |
| 臺大學術典藏 |
2020-03-27T05:28:59Z |
Emphysematous pyelonephritis: Clinical characteristics and prognostic factors
|
Pong Y.-H.; Chen C.-H.; Pu Y.-S.; PO-REN HSUEH; Huang C.-Y.; Chiang B.-J.; Lu Y.-C.; Huang C.-Y.;PO-REN HSUEH;Pu Y.-S.;Chen C.-H.;Pong Y.-H.;Chiang B.-J.;Lu Y.-C. |
| 臺大學術典藏 |
2020-03-27T05:28:58Z |
Predictors of failure of conservative treatment among patients with emphysematous pyelonephritis
|
Chiang B.-J.; Pong Y.-H.; Huang K.-H.; PO-REN HSUEH; Huang C.-Y.; Pu Y.-S.; Lu Y.-C.; Pu Y.-S.;Huang C.-Y.;PO-REN HSUEH;Huang K.-H.;Pong Y.-H.;Chiang B.-J.;Lu Y.-C. |
| 臺大學術典藏 |
2020-03-27T05:28:48Z |
Recommended initial antimicrobial therapy for emphysematous pyelonephritis
|
Pu Y.-S.;Huang C.-Y.;PO-REN HSUEH;Pong Y.-H.;Chiang B.-J.;Hong J.-H.;Lu Y.-C.; Lu Y.-C.; Hong J.-H.; Chiang B.-J.; Pong Y.-H.; PO-REN HSUEH; Huang C.-Y.; Pu Y.-S. |
| 臺大學術典藏 |
2020-03-27T02:03:27Z |
Metallic ureteral stents in malignant ureteral obstruction: Short-term results and radiological features predicting stent failure in patients with non-urological malignancies
|
KAO-LANG LIU; Pu Y.-S.; Yu H.-J.; Wang S.-M.; Hsu J.-S.; Chow P.-M.;Hsu J.-S.;Wang S.-M.;Yu H.-J.;Pu Y.-S.;Kao-Lang Liu; Chow P.-M. |
| 臺大學術典藏 |
2020-03-27T02:03:23Z |
Long-term outcomes of nephrectomy and inferior vena cava thrombectomy in patients with advanced renal cell carcinoma: A single-center experience
|
Pu Y.-S.; Wang S.-M.; Huang K.-H.; Tai H.-C.; Huang C.-Y.; Chow P.-M.; Lin W.-C.; KAO-LANG LIU; Lien C.-C.; Lien C.-C.;Kao-Lang Liu;Chow P.-M.;Lin W.-C.;Tai H.-C.;Huang C.-Y.;Wang S.-M.;Huang K.-H.;Pu Y.-S. |
| 臺大學術典藏 |
2020-03-27T02:03:21Z |
Long-term outcomes of nephrectomy and inferior vena cava thrombectomy in patients with advanced renal cell carcinoma: A single-center experience
|
Lin W.-C.; Tai H.-C.; Huang C.-Y.; Wang S.-M.; Huang K.-H.; Pu Y.-S.; Chou P.-M.; KAO-LANG LIU; Lien C.-C.; Lien C.-C.;Kao-Lang Liu;Chou P.-M.;Lin W.-C.;Tai H.-C.;Huang C.-Y.;Wang S.-M.;Huang K.-H.;Pu Y.-S. |
| 臺大學術典藏 |
2020-03-23T05:54:16Z |
RBMY, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts
|
Chang M.-H.; Ni Y.-H.; Chang C.-J.; Chou W.-C.; Lee Y.-C.; CHIUNG-NIEN CHEN; Pu Y.-S.; Jeng Y.-M.; Lee P.-H.; Hsu H.-C.; Tsuei D.-J.; Tsuei D.-J.;Hsu H.-C.;Lee P.-H.;Jeng Y.-M.;Pu Y.-S.;Chiung-Nien Chen;Lee Y.-C.;Chou W.-C.;Chang C.-J.;Ni Y.-H.;Chang M.-H. |
